Wayne Chu
About Wayne Chu
Wayne Chu, Chief Medical Officer
Wayne Chu is the Chief Medical Officer with a significant track record in the biotechnology and pharmaceutical industry. He has held leadership roles in renowned organizations, including Fate Therapeutics and Genentech, where he contributed to the development of innovative therapeutic molecules. His expertise extends across molecular biology, clinical development, and pediatric hematology-oncology.
Wayne Chu's Education and Training
Wayne Chu graduated cum laude with a B.A. in Molecular Biology from Princeton University. He further advanced his education by earning his M.D. with Distinction in Research from the University of Rochester School of Medicine and Dentistry. Chu's post-graduate clinical training included specialization in pediatric hematology-oncology at Johns Hopkins School of Medicine and the National Cancer Institute.
Wayne Chu's Background in Clinical Development
Wayne Chu has over a decade of experience in clinical development, particularly during his tenure at Genentech. During this period, he was instrumental in pioneering the early clinical development of several key therapeutic approaches, including antibody drug conjugates, checkpoint inhibitors, and immune cell bispecific antibodies. His work has been pivotal in advancing treatments in oncology and other therapeutic areas.
Wayne Chu's Role at Fate Therapeutics
As the former Chief Medical Officer at Fate Therapeutics, Wayne Chu played a crucial role in the strategic and clinical development of the company's product pipeline. His leadership was key in guiding the company's focus on innovative cellular immunotherapies and advancing its clinical programs.